Sarepta Therapeutics to Announce First Quarter 2019 Financial Results and Recent Corporate Developments on May 8, 2019
02 May 2019 - 6:30AM
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision
genetic medicine for rare diseases, will report first quarter 2019
financial results after the Nasdaq Global Market closes on
Wednesday, May 8, 2019. Subsequently, at 4:30 p.m. Eastern Time,
the Company will host a conference call to discuss its first
quarter 2019 financial results and to provide a corporate update.
The conference call may be accessed by dialing
(844) 534-7313 for domestic callers and (574) 990-1451 for
international callers. The passcode for the call is 5198075. Please
specify to the operator that you would like to join the "Sarepta
First Quarter 2019 Earnings Call." The conference call will be
webcast live under the investor relations section of Sarepta's
website at www.sarepta.com and will be archived there following the
call for 90 days. Please connect to Sarepta's website several
minutes prior to the start of the broadcast to ensure adequate time
for any software download that may be necessary.
About Sarepta
Therapeutics
Sarepta is at the forefront of precision genetic
medicine, having built an impressive and competitive position in
Duchenne muscular dystrophy (DMD) and more recently in gene
therapies for 5 Limb-girdle muscular dystrophy diseases (LGMD),
Charcot-Marie-Tooth (CMT), MPS IIIA, Pompe and other CNS-related
disorders, totaling over 20 therapies in various stages of
development. The Company’s programs and research focus span several
therapeutic modalities, including RNA, gene therapy and gene
editing. Sarepta is fueled by an audacious but important mission:
to profoundly improve and extend the lives of patients with rare
genetic-based diseases. For more information, please visit
www.sarepta.com.
Internet Posting of
Information
We routinely post information that may be
important to investors in the 'For Investors' section of our
website at www.sarepta.com. We encourage investors and
potential investors to consult our website regularly for important
information about us.
Source: Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.
Investors: Ian Estepan, 617-274-4052iestepan@sarepta.com
Media:Tracy Sorrentino, 617-301-8566tsorrentino@sarepta.com
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Apr 2024 to May 2024
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From May 2023 to May 2024